title: Anaphylactic shock due to intravesical administration of pirarubicin hydrochloride for the fifth time.
abstract: We report the first case of anaphylaxis induced by intravesical administration of pirarubicin hydrochloride during spinal anesthesia. The patient was a 64-year-old woman being followed up for transitional cell carcinoma of the bladder. Anaphylaxis occurred the fifth time pirarubicin hydrochloride was administered intravesically. Pirarubicin hydrochloride, an anthracycline antitumor antibiotic that is widely used for intravesical instillation chemotherapy, is administered at the end of surgery. Because this is about the time that the patient is leaving the operating room, attention to patient monitoring tends to be divided. Because anaphylaxis may occur at this time, staff should remain vigilant of the risk of anaphylaxis.
authors.affiliation: Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan. Electronic address: izuok125@yahoo.co.jp.
authors.forename: Koji
authors.initials: K
authors.lastname: Sakata
authors.affiliation: Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.
authors.forename: Naokazu
authors.initials: N
authors.lastname: Fukuoka
authors.affiliation: Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.
authors.forename: Kumiko
authors.initials: K
authors.lastname: Tanabe
authors.affiliation: Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.
authors.forename: Motoyasu
authors.initials: M
authors.lastname: Takenaka
authors.affiliation: Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Iida
mesh_terms: D000283:Administration, Intravesical; D000707:Anaphylaxis / Q000188:drug therapy* / Q000209:etiology*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004837:Epinephrine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D013520:Urologic Surgical Procedures / Q000009:adverse effects; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D014662:Vasoconstrictor Agents; D004317:Doxorubicin; C027260:pirarubicin; D004837:Epinephrine
keywords: Anaphylaxis; Intravesical administration; Pirarubicin hydrochloride